You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Treatment Approaches in Early-Stage Bladder Cancer

  • Authors: Neal Shore, MD, FACS; Matthew D. Galsky, MD, FASCO; Stephen B. Williams, MD, MBA, MS, FACS
  • CME / ABIM MOC Released: 11/8/2022
  • Valid for credit through: 11/8/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for urologists, oncologists, surgeons, and other healthcare professionals who care for people with bladder cancer.

The goal of this activity is for learners to be better able to understand and recognize the latest treatment approaches for patients with or without radical cystectomy in early-stage bladder cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Epidemiology of early-stage bladder cancer
    • Treatment approaches for patients who undergo radical cystectomy
    • Emerging therapeutic opportunities for patients who do not undergo radical cystectomy
  • Demonstrate greater confidence in their ability to
    • Use therapeutic options to improve the outcomes for patients with early-stage bladder cancer


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Neal Shore, MD, FACS

    US Chief Medical Officer of Surgery and Oncology
    GenesisCare USA
    Director, Carolina Urologic Research Center
    Myrtle Beach, South Carolina

    Disclosures

    Neal Shore, MD, FACS, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Alessa; Arquer; Astellas; AstraZeneca; Bayer; Bristol Myers Squibb; Clarity; Cold Genesys; Dendreon; Ferring; Foundation Medicine; ImmunityBio Incyte; Invitae; Janssen; Lantheus; Lilly; Merck; Minomic; Myovant; Myriad; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Pfizer; Photocure; Promaxo; Protara Therapeutics; Sanofi; Sesen Bio; Telix Pharmaceuticals; Tolmar; Vaxiion Therapeutics
    Speaker or member of speakers bureau for: Astellas; Bayer; Janssen; Pfizer
    Research funding from: AbbVie; Alessa; Arquer; Astellas; AstraZeneca; Bayer; Bristol Myers Squibb; Clarity; Cold Genesys; Dendreon; Ferring; Foundation Medicine; ImmunityBio Incyte; Invitae; Janssen; Lantheus; Lilly; Merck; Minomic; Myovant; Myriad; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Photocure; Pfizer; Promaxo; Protara Therapeutics; Sanofi; Sesen Bio; Telix Pharmaceuticals; Tolmar; Vaxiion Therapeutics
    Contracted researcher for: AbbVie; Alessa; Arquer; Astellas; AstraZeneca; Bayer; Bristol Myers Squibb; Clarity; Cold Genesys; Dendreon; Ferring; Foundation Medicine; ImmunityBio Incyte; Invitae; Janssen; Lantheus; Lilly; Merck; Minomic; Myovant; Myriad; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Pfizer; Photocure; Promaxo; Protara Therapeutics; Sanofi; Sesen Bio; Telix Pharmaceuticals; Tolmar; Vaxiion Therapeutics
    Stock options from: Alessa; Photocure, Promaxo

  • Matthew D. Galsky, MD, FASCO

    Professor of Medicine
    Icahn School of Medicine at Mount Sinai
    Director, Genitourinary Medical Oncology Program
    Associate Director, Translational Research
    Tisch Cancer Institute
    New York, New York

    Disclosures

    Matthew D. Galsky, MD, FASCO, has the following relevant financial relationships:
    Consultant or advisor for: Alligator; AstraZeneca; Basilea; Bristol Myers Squibb; Curis; Dragonfly; EMD Serono; Fujifilm; Genentech; GlaxoSmithKline; Janssen; Merck; Numab; Pfizer; Rappta Therapeutics; Seagen Inc.; Silverback; UroGen
    Contracted researcher for: Astra Zeneca; Bristol Myers Squibb; Dendreon; Genentech; Merck; Novartis

  • Stephen B. Williams, MD, MBA, MS, FACS

    Associate Chief Medical Officer, UTMB Clear Lake
    Medical Director for High-Value Care, UTMB Health System
    Professor (Tenured)
    Chief, Division of Urology
    The Robert Earl Cone Professorship in Urology
    Director of Urologic Oncology and Director of Urologic Research
    Co-Director, Surgical Outcomes Research Program
    The University of Texas Medical Branch
    Galveston, Texas

    Disclosures

    Stephen B. Williams, MD, MBA, MS, FACS, has no relevant financial relationships.

Editor

  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia Ragoonath-Cameron, MS, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Treatment Approaches in Early-Stage Bladder Cancer

Authors: Neal Shore, MD, FACS; Matthew D. Galsky, MD, FASCO; Stephen B. Williams, MD, MBA, MS, FACSFaculty and Disclosures

CME / ABIM MOC Released: 11/8/2022

Valid for credit through: 11/8/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

A Review of Early-Stage Bladder Cancer

Dr Shore gives an introduction on early-stage bladder cancer.
Neal Shore, MD, FACS

Therapeutic Options for Patients Who Undergo Radical Cystectomy

Dr Galsky delves into the options for patients who undergo radical cystectomy for early-stage bladder cancer.
Matthew D. Galsky, MD, FASCO

Therapeutic Options for Patients Who Do Not Undergo Radical Cystectomy?

What do you do for patients with early-stage bladder cancer who cannot receive radical cystectomy? Dr Williams discusses it here.
Stephen B. Williams, MD, MBA, MS, FACS
 

Educational Impact Challenge

The goal of this activity is for learners to be better able to understand and recognize the latest treatment approaches for patients with or without radical cystectomy in early-stage bladder cancer.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.